Therefore, since the discovery of IGF-IR in the 1980s, there has been great interest among researchers to develop drugs that inhibit IGF-IR signaling (e.g., tyrosine kinase inhibitors and IGF monoclonal antibodies) to treat various cancers. This evidence concerns the gene IGF1R and cancer.